Geron Corp. Stock
Price
Target price
€4.18
€4.18
2.750%
0.111
2.750%
€5.57
05.07.24 / Tradegate
WKN: 902213 / Symbol: GERN / Name: Geron / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Geron Corp. Stock
Geron Corp. gained 2.750% today.
Geron Corp. is currently one of the favorites of our community with 16 Buy predictions and no Sell predictions.
As a result the target price of 5 € shows a slightly positive potential of 19.5% compared to the current price of 4.18 € for Geron Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Geron Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Geron Corp. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Geron Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Geron Corp. | 2.750% | -2.437% | 10.374% | 38.554% | 105.437% | 227.368% | 221.485% |
| Ardelyx Inc. | 0.220% | -19.513% | -22.472% | 60.393% | -15.363% | -26.985% | - |
| Evolus Inc | 2.620% | -1.546% | -16.957% | 48.062% | 5.525% | -9.048% | - |
| Brainstorm Cell | -4.330% | -7.439% | -28.031% | -82.514% | 43.142% | -89.565% | -90.957% |
Comments
Geron Co. (NASDAQ: GERN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $9.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at Stifel Nicolaus from $6.00 to $7.00. They now have a "buy" rating on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its price target raised by analysts at Needham & Company LLC from $5.00 to $6.00. They now have a "buy" rating on the stock.
Show more
Ratings data for GERN provided by MarketBeat
News
Is Geron Stock a Buy Following Its First New Drug Approval?
Shares of Geron (NASDAQ: GERN) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades.
On June 6, the U.S. Food
Geron Corporation: FDA Approval Fuels Stock Price Surge
The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation (NASDAQ: GERN) into the spotlight, sparking a surge in Geron’s stock price and attracting heightened attention
Geron (GERN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q1 2024 Earnings CallMay 02, 2024, 8:00 a.m. ET
Operator
Source Fool.com